News Search Results
Jun 30, 2025, 09:00 ET Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
responsible for building and managing the west coast life sciences and biotechnology investment banking business. He also held roles as Managing Director of Investment Banking in the Global Healthcare Group at UBS, focused on the biotechnology sector, and as Managing Director of Investment Banking at Leerink
More news about: Kyverna Therapeutics
Jun 30, 2025, 09:00 ET UL Research Institutes' Chemical Insights Names New Executive Director
director of the Center for Computational Toxicology and Exposure. Before joining the EPA, he performed bioinformatics and genomics research in the biotechnology sector and gained experience in high-throughput screening and in vitro assay development in the biopharma sector. He also worked as an investigator
More news about: UL Research Institutes
Jun 30, 2025, 09:00 ET Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs
solutions, and realize those possibilities. Noul has commercialized the world's first AI-powered diagnostic lab, miLab™, through convergence of AI, biotechnology, and compact robotics. The miLab™ Platform is the only solution that fully automates the microscopic diagnostic process—from sample preparation
More news about: Noul
Jun 30, 2025, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jun 30, 2025, 08:31 ET AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under
More news about: AbbVie
Jun 30, 2025, 08:30 ET Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
information on the durability of Xanamem's benefits." About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong
More news about: Actinogen Medical Limited
Jun 30, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Jun 30, 2025, 08:00 ET Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
June 30, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Jun 30, 2025, 08:00 ET Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting
solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about
More news about: Avant Technologies Inc.
Jun 30, 2025, 07:45 ET ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging
ARTAN Bio, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and
More news about: Syenex
Jun 30, 2025, 07:00 ET Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
acquisition of the Company or the exclusive license of pelareorep. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Jun 29, 2025, 16:43 ET Sealless Pumps Market to Reach $8.2 Billion by 2032, Growing at a CAGR of 10.6% from 2025, Says Meticulous Research®
pumps, and varying industry standards across different applications. However, significant opportunities exist in emerging pharmaceutical and biotechnology markets, development of smart pump technologies and AI-powered monitoring systems, expansion in developing markets with growing industrial infrastructure,
More news about: Meticulous Market Research Private Limited
Jun 27, 2025, 19:04 ET HEPA Filters Market to Reach $5.8 Billion by 2032, Growing at a CAGR of 7.9% from 2025, Says Meticulous Research®
adoption of HEPA filters in residential sectors for indoor air purification. The market's expansion is fueled by the expansion of healthcare and biotechnology sectors, growth in smart homes and connected air filtration systems, and the development of hybrid filtration technologies combining HEPA with activated
More news about: Meticulous Market Research Pvt. Ltd
Jun 27, 2025, 18:25 ET Freeze Drying Equipment Market to Surge from USD 4.9 Billion to USD 8.4 Billion by 2032 - Meticulous Research®
sustained demand for freeze-dried food products across diverse consumer segments. Pharmaceutical & Biotechnology Drives Premium Growth The pharmaceutical and biotechnology sector exhibits the highest growth potential through increasing demand for lyophilized drug products, vaccine
More news about: Meticulous Market Research Pvt. Ltd
Jun 27, 2025, 13:41 ET Kalorama Highlights Key Trends and Breakthroughs in Blood Typing Market in New Report
division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Media Contact:Name: Alisa AlvichTitle:
More news about: Kalorama Information
Jun 27, 2025, 12:00 ET Frost & Sullivan Recognizes Leading Organizations with Prestigious 2025 Best Practices Awards
airsysnorthamerica.com Novotech2025 Global Biotechnology Contract Research Organization Company of the Year AwardNovotech has redefined the biotech CRO landscape with a client-centric approach
More news about: Frost & Sullivan
Jun 27, 2025, 12:00 ET Frost & Sullivan Recognizes Leading Organizations with Prestigious 2025 Best Practices Awards
airsysnorthamerica.com Novotech2025 Global Biotechnology Contract Research Organization Company of the Year AwardNovotech has redefined the biotech CRO landscape with a client-centric approach
More news about: Frost & Sullivan
Jun 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jun 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jun 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jun 27, 2025, 09:00 ET Debut Named to TIME's List of the TIME100 Most Influential Companies 2025
"This global recognition affirms Debut's pioneering achievements in innovating higher-performing products and ingredients in beauty using AI and biotechnology," said Joshua Britton, PhD, Founder and CEO of Debut. "I am incredibly proud and honored to receive this accolade
More news about: Debut
Jun 27, 2025, 09:00 ET MEET THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE BOARD OF VISITORS
exceptional roster of new board members, representing a unique range of backgrounds and professional expertise in finance, law, pharmaceuticals, biotechnology and public policy to complement our current members," said
More news about: University of Maryland School of Medicine
Jun 27, 2025, 06:49 ET Regenics Appoints Brynjólfur Gísli Eyjólfsson as Chair of the Board
Investments (IS Haf Fjárfestingar slhf.) is a private equity fund managed by Iceland Funds with a focus on sustainable investments in seafood, marine biotechnology, and the blue economy. The fund is the largest investor in Nordic Blue hf., an Icelandic investment company with significant holdings in Regenics.
More news about: Regenics AS
Jun 26, 2025, 20:05 ET Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
support our clients rely on to advance the next generation of cell and gene therapies." About SynthegoSynthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health.
More news about: Synthego
Jun 26, 2025, 18:17 ET Faruqi & Faruqi Reminds Fortrea Holdings Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 1, 2025 - FTRE
from buy to hold. Among other things, the Jefferies Report cited perceived weaknesses in the Company's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are "not as material as [o]ne [m]ight think," stating
More news about: Faruqi & Faruqi, LLP